ION-1S

ION-1S

Price range: $39.00 through $99.00

For research purposes only. Not for human or animal use & not FDA-approved. By purchasing, you confirm you are 21 or older and qualified researcher.

Quantity Price
4 - 5 $35.10
6 - 9 $32.76
10 + $29.25
Money Back Guarantee Guaranteed Quality Customer Support Fast Shipping
SKU: N/A Categories: , ,

Description

ION-1S (Research Compound)

Tagline: Advanced ION-1s Analogue

Product Description

ION-1S is a synthetic analogue of glucagon-like peptide-1 (GLP-1), designed for laboratory and scientific research only. Researchers study this compound for its unique role in metabolism regulation, insulin signaling, and cardiovascular pathways. Due to its high stability and structural similarity to endogenous GLP-1, ION-1S offers consistent results in controlled experimental environments.

This compound is not intended for human use, treatment, or diagnostic purposes. All applications must remain strictly within research settings.

Why Researchers Choose GLP-1S

  • High purity for reproducible results

  • Strong stability under proper storage conditions

  • Reliable solubility for precise dosing in experiments

  • Widely studied in metabolic and cardiovascular research models

  • Easy to handle and reconstitute for laboratory protocols

Important Note

For laboratory and scientific research only. Not for human consumption.Semaglutide GLP

Details

Specification Information
Form Lyophilized powder
Shelf Life Up to 24 months (lyophilized)
Intended Use Laboratory research only
Storage –20°C (lyophilized), –80°C after reconstitution

Research

Research

Metabolism & Insulin Sensitivity

ION-1S is commonly studied for its effects on glucose metabolism and insulin regulation. Research indicates that GLP-1 analogues may influence beta-cell activity and insulin secretion in animal and cell models [1].

Cardiovascular Function

Studies explore the compound’s role in cardiovascular health, particularly in how GLP-1 receptor activity may impact blood pressure regulation and vascular inflammation [2].

Appetite & Energy Balance

Experimental data suggest that GLP-1S can influence hypothalamic signaling pathways, affecting food intake and energy expenditure in controlled studies [3].

Neuroprotection & Cognitive Health

Preclinical findings indicate potential roles for GLP-1 analogues in neuroprotection and memory pathways, though mechanisms are still under investigation [4].

References

  1. Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev. https://journals.physiology.org/doi/pdf/10.1152/physrev.00034.2006

  2. Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in cardiovascular outcomes: state-of-the-art. Lancet Diabetes Endocrinol.
    https://europepmc.org/article/MED/34181914

  3. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH (2014). Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. Diabetes Obes Metab.
    https://europepmc.org/articles/PMC4052428

  4. Hölscher C (2019). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. Prog Brain Res.
    https://europepmc.org/article/MED/23999914

  5. Drucker DJ (2018). “Mechanisms of action and therapeutic application of GLP-1 analogues.” Cell Metabolism.
    https://www.cell.com/cell-metabolism/fulltext/S1550-4131%2818%2930179-7

Mechanism of Action

Mechanism of Action

  • Mimics endogenous GLP-1 structure, binding to GLP-1 receptors [1].

  • Activates signaling cascades that regulate insulin release and glucose metabolism [2].

  • Slows gastric emptying, influencing appetite regulation in experimental models [3].

  • Enhances cellular energy balance through AMPK and related pathways [4].

  • Modulates inflammation and oxidative stress in preclinical systems [5].

References

  1. Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev. https://journals.physiology.org/doi/pdf/10.1152/physrev.00034.2006

  2. Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in cardiovascular outcomes: state-of-the-art. Lancet Diabetes Endocrinol.
    https://europepmc.org/article/MED/34181914

  3. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH (2014). Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. Diabetes Obes Metab.
    https://europepmc.org/articles/PMC4052428

  4. Hölscher C (2019). Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. Prog Brain Res.
    https://europepmc.org/article/MED/23999914

  5. Drucker DJ (2018). “Mechanisms of action and therapeutic application of GLP-1 analogues.” Cell Metabolism.
    https://www.cell.com/cell-metabolism/fulltext/S1550-4131%2818%2930179-7

Certificate of Authenticity

 

Related products

  • MLT I
  • TB-500
  • §-31
  • GLOW - 70mg